INCIDENCE AND SIGNIFICANCE OF TUMOR EGFR AND KRAS MUTATIONS IN GREEK METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH 1ST LINE CHEMOTHERAPY

被引：0

作者：

Linardou, Helena ^{[1
]}

Pectasides, Dimitrios ^{[1
]}

Agelaki, Sophia ^{[1
]}

Kotoula, Vassiliki ^{[1
]}

Karavasilis, Vasilios ^{[1
]}

Eleftheraki, Anastasia G. ^{[1
]}

Samantas, Epaminondas ^{[1
]}

Kotsakis, Athanasios ^{[1
]}

Razis, Evangelia ^{[1
]}

Fountzilas, George ^{[1
]}

机构：

[1] Hellen Cooperat Oncol Grp, Athens, Greece

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

KRAS; EGFR; mutations; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.06-057

引用

页码：S503 / S503

页数：1

共 50 条

[31] Efficacy of PD-1 inhibitors in patients with metastatic non-small cell lung cancer (NSCLC) with KRAS or EGFR T790M mutations
Sharma, Nitika
Stroud, Chipman Robert Geoffrey
Walker, Paul R.
Cherukuri, Sulochana Devi
Muzaffar, Mahvish
Cherry, Cynthia R.
Parent, Teresa
Hardin, Jessica
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer
Zhao, C.
Li, X.
Su, C.
Chen, X.
Ren, S.
Zhou, C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S507 - S507
[33] EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer
Kimura, Hideharu
Kasahara, Kazuo
Shibata, Kazuhiko
Sone, Takashi
Yoshimoto, Akihiro
Kita, Toshiyuki
Ichikawa, Yukari
Waseda, Yuko
Watanabe, Kazuyoshi
Shiarasaki, Hiroki
Ishiura, Yoshihisa
Mizuguchi, Masayuki
Nakatsumi, Yasuto
Kashii, Tatsuhiko
Kobayashi, Masashi
Kunitoh, Hideo
Tamura, Tomohide
Nishio, Kazuto
Fujimura, Masaki
Nakao, Shinji
[J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 260 - 267
[34] Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer
Ying, K.
Xu, N.
Jiang, H.
Liu, Y.
Zhou, H.
Wang, S.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1047
[35] Leptomeningeal metastases in non-small cell lung cancer patients with EGFR mutations
Li, Y-S.
Jiang, B-Y.
Wu, Y-L.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[36] Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients
Wen, Linfang
Wang, Shenghao
Xu, Weiran
Xu, Xiaofeng
Li, Mei
Zhang, Yaqiong
Du, Xiaobing
Liu, Shuang
[J]. ANNALS OF DIAGNOSTIC PATHOLOGY, 2020, 49
[37] Detection of EGFR and KRAS somatic mutations in tumor tissue and peripheral blood by a liquidchip technology for patients with advanced non-small cell lung cancer
Zhang, Shucai
Zhang, Hui
Yang, Xinjie
Li, Xi
Qin, Na
Xu, Jiasen
Yang, Huiyi
Zheng, Yong-Qing
Yu, Gang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[38] ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
Gainor, Justin F.
Varghese, Anna M.
Ou, Sai-Hong Ignatius
Kabraji, Sheheryar
Awad, Mark M.
Katayama, Ryohei
Pawlak, Amanda
Mino-Kenudson, Mari
Yeap, Beow Y.
Riely, Gregory J.
Iafrate, A. John
Arcila, Maria E.
Ladanyi, Marc
Engelman, Jeffrey A.
Dias-Santagata, Dora
Shaw, Alice T.
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (15) : 4273 - 4281
[39] Implications of KRAS Mutations on Outcomes in Non-small Cell Lung Cancer Treated With Radiation Therapy
Welsh, J. W.
Likacheva, A.
Byers, L. A.
Bhardwaj, V.
Diao, L.
Wang, J.
Ang, K.
Komaki, R.
Kim, E.
Heymach, J. V.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S70 - S70
[40] EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer
Wu, Meina
Zhao, Jun
Song, Sonya Wei
Zhuo, Minglei
Wang, Xin
Bai, Hua
Wang, Shuhang
Yang, Lu
An, Tongtong
Zhang, Yan
Duan, Jianchun
Wang, Yuyan
Guo, Qingzhi
Liu, Xuyi
Liu, Ninghong
Wang, Jie
[J]. LUNG CANCER, 2010, 67 (03) : 343 - 347

← 1 2 3 4 5 →